A study to ascertain the optimum starting dose of subcutaneous (SC) C.E.R.A. for maintenance treatment of anaemia in paediatric patients with chronic kidney disease (CKD) on dialysis or not yet on dialysis
This oral presentation provides an overview of the study design, eligibility criteria and outcomes for key endpoints from the Phase II, open-label, single-arm, multicentre SKIPPER (NH19708; NCT03552393) clinical study. The study assessed the optimum starting dose of C.E.R.A. SC using the same conversion factors defined in the DOLPHIN study for C.E.R.A IV, for maintenance treatment of anemia in pediatric patients with chronic kidney disease on dialysis or not yet on dialysis, when switching from stable SC maintenance treatment with epoetin alfa/beta or darbepoetin alfa.